A dynamic prediction engine to prevent chemotherapy-induced nausea and vomiting

Abstract Background Cancer remains the second major cause of death in the United States over the last decade. Chemotherapy is a core component of nearly every cancer treatment plan. Chemotherapy-Induced Nausea and Vomiting (CINV) are the two most dreadful and unpleasant side-effects of chemotherapy for cancer patients. Several patient-specific factors affect the risk of CINV. However, none of the guidelines consider those factors. Not all of the patients have the similar emetic risk of CINV. Despite the improvements in CINV management, as many as two-thirds of chemotherapy patients still experience some degree of CINV. As a result, physicians use their personal experiences for CINV treatment, which leads to inconsistent managements of CINV. Objective The overall objective of this study is to improve the prevention of CINV using precise, personalized and evidence-based antiemetic treatment before chemotherapy. In CINV prediction, one of the interesting factors is that CINV has two distinct and complex pathophysiologic phases: acute and delayed. In addition, the risk factors and their associations are different for different emetogenic chemotherapies (e.g., low, moderate, and high). There are six contexts considering the combination of phases and emetogenicity levels. This will require the creation of six different models. Instead, our objective was to describe a single framework named “prediction engine” that can perform prediction query without losing the sensitivity to each context. The prediction engine discovers how the patient-related variables and the emetogenecity of chemotherapy are associated with the risk of CINV for each phase. Methods This was a single-center retrospective study. The data were collected by retrospective record review from the electronic medical record system used at the University of Missouri Ellis Fischel Cancer Center. An association rule-based dynamic and context-sensitive Prediction Engine has been developed. Physicians receive feedback about CINV risks of patients from the CINV decision support system based on patient-specific factors. Results The prediction performance of the system outperformed many popular prediction methods and all the results of CINV risk prediction published in the literature. Best prediction performance was achieved using the rule-ranking approach. The accuracy, sensitivity, and specificity were 87.85 %, 87.54 %, and 88.2 %, respectively. Conclusions The system used the patient-specific risk factors for making personalized treatment recommendations for CINV. It solved a real clinical problem that will shorten the gap between clinical practices and evidence-based guidelines for CINV management leading to the practice of personalized and precise treatment recommendation, better life quality of patient, and reduced healthcare cost. The approach presented in this article can be applied to any other clinical predictions.

[1]  S. Grunberg,et al.  Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes. , 2009, Clinical journal of oncology nursing.

[2]  G. Dranitsaris,et al.  Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting. , 2012, Current oncology.

[3]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[4]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Ian H. Witten,et al.  The WEKA data mining software: an update , 2009, SKDD.

[6]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Yelle,et al.  Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. , 2005, Supportive cancer therapy.

[8]  S B Kaye,et al.  On the receiving end--patient perception of the side-effects of cancer chemotherapy. , 1983, European journal of cancer & clinical oncology.

[9]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[10]  Jian Pei,et al.  Mining frequent patterns without candidate generation , 2000, SIGMOD 2000.

[11]  A. Bardia,et al.  Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. , 2011, Journal of palliative medicine.

[12]  A. Molassiotis,et al.  Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting , 2013, Supportive Care in Cancer.

[13]  E. Bayliss,et al.  Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study , 2011, Supportive Care in Cancer.

[14]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates , 2010, Cancer.

[15]  R. Bresalier,et al.  Gastrointestinal complications of oncologic therapy , 2008, Nature Clinical Practice Gastroenterology &Hepatology.

[16]  Edward Chu,et al.  A history of cancer chemotherapy. , 2008, Cancer research.

[17]  Elissa V. Klinger,et al.  Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting , 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[18]  E. Ming,et al.  Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings , 2007, Supportive Care in Cancer.

[19]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[20]  Jen‐Shi Chen,et al.  Reduced Maintenance of Complete Protection From Emesis for Women During Chemotherapy Cycles , 2003, American journal of clinical oncology.

[21]  P. Feyer,et al.  Update and new trends in antiemetic therapy: the continuing need for novel therapies. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  S. Kalghatgi,et al.  Pancreatic Cancer in Chronic Pancreatitis , 2015, Indian Journal of Surgical Oncology.

[23]  Xueming Li,et al.  ACCF: Associative Classification Based on Closed Frequent Itemsets , 2008, 2008 Fifth International Conference on Fuzzy Systems and Knowledge Discovery.

[24]  A. Hüsler,et al.  Chemotherapy-induced nausea and vomiting in routine practice: a European perspective , 2004, Supportive Care in Cancer.

[25]  A. Molassiotis,et al.  A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre , 2008, Supportive Care in Cancer.

[26]  AgrawalRakesh,et al.  Mining association rules between sets of items in large databases , 1993 .

[27]  Panagiotis Mavros,et al.  Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Naik,et al.  Chemotherapeutic agents and the skin: An update. , 2008, Journal of the American Academy of Dermatology.

[29]  H. Eichler,et al.  The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  J. Lucas,et al.  Summary health statistics for U.S. adults: national health interview survey, 2012. , 2014, Vital and health statistics. Series 10, Data from the National Health Survey.

[31]  M. Lacouture,et al.  Dermatologic toxicities of targeted anticancer therapies. , 2010, The journal of supportive oncology.

[32]  L. Schwartzberg Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. , 2007, The journal of supportive oncology.

[33]  J. Durant The problem of nausea and vomiting in modem cancer chemotherapy , 1984, CA: a cancer journal for clinicians.

[34]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[35]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[36]  J. Gayle,et al.  Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States , 2011, Journal of medical economics.

[37]  Tomasz Imielinski,et al.  Mining association rules between sets of items in large databases , 1993, SIGMOD Conference.

[38]  Wynne Hsu,et al.  Integrating Classification and Association Rule Mining , 1998, KDD.

[39]  P. Maisonneuve,et al.  Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. , 2010, Best practice & research. Clinical gastroenterology.

[40]  G. Dranitsaris,et al.  Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting. , 2012, The journal of supportive oncology.

[41]  V. Georgiou,et al.  The impact of cytotoxic chemotherapy--perspectives from patients, specialists and nurses. , 1992, European journal of cancer.

[42]  B. Daniele,et al.  The cost of chemotherapy-induced nausea and vomiting in Italy , 2006, Supportive Care in Cancer.

[43]  N. Aaronson,et al.  Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study , 2011, Supportive Care in Cancer.

[44]  G. Morrow Chemotherapy‐related nausea and vomiting: Etiology and management , 1989, CA: a cancer journal for clinicians.

[45]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[46]  D. Bodurka,et al.  Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer , 2005, Supportive Care in Cancer.

[47]  D. Osoba,et al.  Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Paus,et al.  Protection against chemotherapy-induced alopecia: targeting ATP-binding cassette transporters in the hair follicle? , 2013, Trends in pharmacological sciences.

[49]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[50]  L. Menditto,et al.  Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population , 2011, Supportive Care in Cancer.

[51]  M. Kris,et al.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  Ya-Chen Tina Shih,et al.  Costs of uncontrolled chemotherapy‐induced nausea and vomiting among working‐age cancer patients receiving highly or moderately emetogenic chemotherapy , 2007, Cancer.

[53]  W. Voigt,et al.  Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management , 2010, Therapeutic advances in medical oncology.

[54]  P. Viale,et al.  Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting. , 2012, Clinical journal of oncology nursing.

[55]  Xianglin L. Du,et al.  Adjuvant Chemotherapy and Risk of Gastrointestinal, Hematologic, and Cardiac Toxicities in Elderly Patients With Stage III Colon Cancer , 2012, American journal of clinical oncology.

[56]  G. Marks,et al.  The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Dante diTommaso,et al.  Quantifying the role of PSA screening in the US prostate cancer mortality decline , 2008, Cancer Causes & Control.

[58]  B. Nevidjon,et al.  Controlling emesis: evolving challenges, novel strategies. , 2010, The journal of supportive oncology.

[59]  C. Heckler,et al.  Insight in the prediction of chemotherapy-induced nausea , 2010, Supportive Care in Cancer.

[60]  Ralf Paus,et al.  Pathobiology of chemotherapy-induced hair loss. , 2013, The Lancet. Oncology.

[61]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.